Mallinckrodt PLC CEO Confronts Short Seller Andrew Left But Doesn't Appear to Answer His QuestionsMark Melin
Troubled health care roll-up artist Valeant is like a bunch of “choir boys” when compared pharmaceutical concern Mallinckrodt, short seller Andrew Left of Citron Research said on CNBC Wednesday after the close, where he was confronted by the firm's CEO.
Left was short and vocal regarding Valeant, says its the tip of . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email email@example.com or click Chat.